MARKET

RGNX

RGNX

Regenxbio
NASDAQ
18.75
+0.35
+1.90%
Opening 12:29 02/22 EST
OPEN
18.41
PREV CLOSE
18.40
HIGH
18.99
LOW
18.27
VOLUME
112.52K
TURNOVER
0
52 WEEK HIGH
25.32
52 WEEK LOW
11.83
MARKET CAP
824.85M
P/E (TTM)
-3.1344
1D
5D
1M
3M
1Y
5Y
Raymond James Reinstates Outperform on Regenxbio, Announces $45 Price Target
Benzinga · 1d ago
Review Of The Developmental Landscape Of Long-Acting Anti-VEGF Therapies In Wet-AMD
Seeking Alpha · 2d ago
Weekly Report: what happened at RGNX last week (0212-0216)?
Weekly Report · 3d ago
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
REGENXBIO Inc reported additional interim safety and efficacy in the Phase 1/2 Duchenne muscular dystrophy trial of RGX-202. The company also announced topline results from the phase 2 trial of rgx-121 in Hunter syndrome. Wedbush reiterates the Neutral rating on rx-202 with a price target of $21. RGNX shares are up 9.50% at $17.75.
Benzinga · 02/12 19:35
Wedbush Reiterates Neutral on Regenxbio, Maintains $21 Price Target
Benzinga · 02/12 13:25
Maintaining Hold on RegenXBio: A Cautious Stance Amidst Pipeline Uncertainties and Market Competition
TipRanks · 02/12 11:45
The 1-Minute Market Report February 12, 2024
Home Market Outlook Today's Market The 1-Minute Market Report February 12, 2024. For the week just past, the S&P 500 was up 1.4%. The best performer last week was the ProShares Bitcoin Strategy ETF, up 10.8% in one week. The market set 10 new highs in 16 days.
Seeking Alpha · 02/12 09:47
Weekly Report: what happened at RGNX last week (0205-0209)?
Weekly Report · 02/12 09:26
More
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company, which is focused on providing curative potential of gene therapy. Its investigational gene therapies are designed to deliver functional genes to address genetic defects in cells. The Company’s investigational AAV Therapeutics include RGX-314, RGX-202, RGX-121, RGX-111 and RGX-181 and RGX-381. RGX-314 is meant for the treatment of large patient populations impacted by wet age-related macular degeneration (wet AMD), diabetic retinopathy and other chronic retinal diseases. RGX-202 is developed to treat Duchenne muscular dystrophy, one of the common fatal genetic disorders affecting children. RGX-121, RGX-111 and RGX-181 are developed to treat Mucopolysaccharidosis type II, Mucopolysaccharidosis type I, and late infantile neuronal ceroid lipofuscinosis type II (CLN2 disease), all of which are progressive, neurodegenerative lysosomal storage disorders. RGX-381 is developed to treat the ocular manifestations of CLN2 disease.

Webull offers Regenxbio Inc stock information, including NASDAQ: RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.